A randomized, multicenter, phase II/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteograstim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10-09
Titel:
A randomized, multicenter, phase II/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteograstim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10-09
Auteur:
Lee, Ki Hyeong Kim, Ji-Yeon Lee, Moon Hee Han, Hye Sook Lim, Joo Han Park, Keon Uk Park, In Hae Cho, Eun Kyung Yoon, So Young Kim, Jee Hyun Choi, In Sil Park, Jae Hoo Choi, Young Jin Kim, Hee-Jun Jung, Kyung Hae Kim, Si-Young Oh, Do-Youn Im, Seock-Ah